WHO Report: Progress and Challenges in Eliminating HIV, Hepatitis, and STIs by 2030

The World Health Organization has released a comprehensive progress assessment report revealing that while global initiatives have cut AIDS-related deaths by 57% since 2010, epidemics of HIV, viral hepatitis, and sexually transmitted infections continue to face severe disruption from funding cuts, rising antimicrobial resistance, and persistent regional healthcare inequalities.

In Plain English: The Clinical Takeaway

• What’s working: Expanded access to antiretroviral treatment has brought 32 million people living with HIV under care globally by the end of 2025, sharply driving down transmission and mortality rates.
• Where the gaps remain: Viral hepatitis is now claiming roughly 1.3 million lives annually, and bacterial sexually transmitted infections like gonorrhea are increasingly developing resistance to standard antibiotic treatments.
• The next intervention wave: Public health frameworks are shifting toward integrated primary care delivery, alongside long-acting prevention tools like twice-yearly injectable lenacapavir and doxycycline post-exposure prophylaxis.

Evaluating Global Progress and Persistent Epidemic Burdens

Published in conjunction with the 26th International AIDS Conference (AIDS 2026) and ahead of World Hepatitis Day, the new World Health Organization report evaluates implementation progress across the Global Health Sector Strategies for 2022 through 2030. According to the assessment, cumulative global efforts have yielded remarkable gains in specific arenas. New HIV infections have dropped by 42% since 2010, while annual hepatitis B infections have fallen by 32% since 2015.

Despite these clinical milestones, acute vulnerabilities remain visible across public health infrastructure. Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, noted in the report that while these trends demonstrate the power of sustained scientific investment, progress can be swiftly undone by humanitarian emergencies and international funding disruptions. An estimated 9 million individuals still lack access to life-saving antiretroviral therapy, and new HIV diagnoses are climbing among key demographics, including men who have sex with men, sex workers, people who inject drugs, transgender individuals, and incarcerated populations.

Global Epidemic Metrics and Trajectories (WHO Assessment)

Condition	Baseline Metric	Current Status	Primary Obstacle
HIV/AIDS	57% drop in deaths since 2010	32 million receiving treatment (2025)	Donor funding cuts and declining PrEP access
Viral Hepatitis	32% drop in Hep B infections since 2015	1.3 million deaths globally (2024)	Low diagnosis and treatment coverage rates
Sexually Transmitted Infections	Improved syphilis screening in pregnancy	Rising STI incidence rates	Antimicrobial resistance in gonorrhea

The global fight against viral hepatitis and sexually transmitted infections faces distinct systemic hurdles. While hepatitis C-related deaths have decreased by 12% globally since 2015, overall mortality linked to hepatitis B has climbed by 17% over the same timeframe. Low diagnostic testing rates and constrained treatment coverage continue to impede disease management, despite the availability of potent antiviral medications.

Meanwhile, sexually transmitted infections present a compounding clinical threat driven by antimicrobial resistance. Public health authorities report that standard pharmacological regimens for treating gonorrhea are losing efficacy against mutating bacterial strains. Compounding this, international donor funding reductions throughout 2025 severely impacted pre-exposure prophylaxis (PrEP) delivery programs. Although several domestic governments have mobilized domestic resources to bridge financial gaps, surveillance data indicate an overall contraction in preventive pharmaceutical distribution.

Integration, Innovation, and Modernized Delivery Frameworks

To realign the 2030 targets, the World Health Organization emphasizes the operational restructuring of healthcare delivery through primary health care models. Systems demonstrating the highest clinical efficacy are those merging HIV, hepatitis, and STI services directly with tuberculosis treatment, maternal-child health initiatives, and noncommunicable disease care. Furthermore, eliminating vertical mother-to-child transmission of HIV, syphilis, and hepatitis B remains a central priority as nations pursue formal validation from international health authorities.

Technological advancements offer targeted solutions to these structural deficits. The introduction of long-acting antiretroviral formulations, such as the WHO-recommended twice-yearly injectable lenacapavir—currently rolling out across multiple countries—represents a major pharmacological advancement over daily oral regimens. Similarly, the implementation of doxycycline post-exposure prophylaxis (doxycycline PEP) provides a robust biomedical intervention to mitigate bacterial STI transmission among high-risk cohorts. Alongside these pharmacological tools, the release of updated consolidated HIV service delivery guidelines and routine surveillance frameworks aims to optimize local clinical data utilization.

Contraindications & When to Consult a Doctor

Outlook on the 2030 Strategic Horizon

Achieving the Sustainable Development Goal targets for 2030 requires bridging the chasm between available medical innovation and real-world patient access. By embedding community-led monitoring systems, expanding interoperable digital health networks, and securing sustained domestic and international financing, healthcare systems can stabilize vulnerable patient pipelines. The path forward relies less on discovering new science and more on equitable, resilient implementation.

References

• World Health Organization. (2026). Assessing progress in implementing the Global Health Sector Strategies on HIV, viral hepatitis and sexually transmitted infections for 2022–2030. Geneva: World Health Organization.
• World Health Organization. (2026). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization.
• World Health Organization. (2022). Global health sector strategies on HIV, viral hepatitis and sexually transmitted infections for 2022–2030. Geneva: World Health Organization.